Edgar Filing: Cara Therapeutics, Inc. - Form 4

Cara Thera Form 4	peutics, Inc.									
January 31,	, 2014									
FORM			GEOU	DIFIE					PPROVAL	
	UNITED	SIAIES		ashington			COMMISSIO	N OMB Number:	3235-0287	
if no lo	this box				Expires:	January 31, 2005				
subject Section Form 4 Form 5	to SIATEN 16. or			NGES IN SECUI	Estimated burden hou response	average urs per				
obligati may co <i>See</i> Inst 1(b).	ntinue. Section 170	(a) of the	Public U	Jtility Hol	ding Cor		nge Act of 1934, of 1935 or Secti 940			
(Print or Type	e Responses)									
1. Name and Menzaghi	Symbol	er Name an herapeutio		-	5. Relationship of Reporting Person(s) to Issuer					
(Last)	Middle)		•			(Check all applicable)				
C/O CARA INC., 1 PA		of Earliest T Day/Year) 2014	ransaction		Director 10% Owner X_ Officer (give title Other (specify below) below) VP-Research & Development					
	4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
SHELTON	N, CT 06484						Person		sporting	
(City)	(State)	(Zip)	Tal	ole I - Non-J	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
D . I D		c 1 1		Code V		(D) Price				
Reminder: Re	eport on a separate line	e for each cl	lass of sec	urities bene	-	-	or indirectly.	oction of	SEC 1474	
					inforn requi	nation cont red to response ays a current	ained in this forn ond unless the fo ntly valid OMB co	n are not rm	(9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Cara Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/	Day/Year)	(Instr.	8)	Acquired or Dispose (D) (Instr. 3, 4 and 5)	ed of				
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 11	01/30/2014			А		40,000		<u>(1)</u>	01/30/2024	Common Stock	40,000
Reporting Owners												
Reporting Owner Name / Address		Relationships Director 10% Owner Officer						Other				
Menzaghi Frederique Ph.D. C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON, CT 06484				VP-Research & Development								
Signat	ures											
/s/Darren l Attorney-ir			01/3	51/2014								
**Signatu	ire of Reporting Per	rson	I	Date								

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

One-fourth (1/4th) of the shares shall vest and become exercisable on January 30, 2015; the balance of the shares shall vest and become
 (1) exercisable in a series of 36 successive equal monthly installments measured from January 30, 2015, subject to the reporting person's continuous service with the issuer as of each such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.